The global trade chessboard just got a shake-up, and Indian markets weren't spared the impact. On April 2, 2025, US President Donald Trump announced a steep 26 per cent reciprocal tariff on Indian imports. This move is part of his broader push to impose a 10 per cent baseline tariff on all US trade partners starting April 5. The goal? To address trade imbalances by making imports from surplus economies more expensive.
Markets didn't take the news lightly. Within hours, the Nifty 50 slid to 23,192., while the BSE Sensex dipped to 76,153. Analysts voiced concerns that such a hefty tariff could rattle global trade flows, impact corporate earnings and potentially slow India's economic growth.
But not everyone was caught in the downturn. The pharmaceutical sector found itself in a rare sweet spot thanks to a temporary exemption from the new tariffs. Investors piled into pharma stocks, pushing Dr Reddy and Gland Pharma, making them the top gainers of the day.
This episode once again highlights how deeply interconnected financial markets and global trade policies are. A single announcement from the White House sent shockwaves across sectors, reminding investors that policy shifts can turn the tide in an instant.
Disclaimer: This article was composed with the assistance of artificial intelligence. While we've taught our digital scribe to behave, we still recommend a pinch of healthy scepticism alongside your reading. Enjoy - and proceed with a knowing smile!
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
